Literature DB >> 10525759

A PET study of D(1)-like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain.

Y H Chou1, P Karlsson, C Halldin, H Olsson, L Farde.   

Abstract

RATIONALE: Several positron emission tomography (PET) studies have shown that radioligand binding to D(2)-like dopamine receptors competes with endogenous dopamine.
OBJECTIVE: The purpose of this PET study was to examine the effect of amphetamine and reserpine on D(1)-like dopamine receptor binding.
METHODS: Three Cynomolgus monkeys were examined with the radioligands [(11)C]SCH 23390 or [(11)C]NNC 112 at baseline condition and after pretreatment with amphetamine (2 mg/kg IV). The B/F values (binding potential) in the striatum and the neocortex were calculated at transient equilibrium. In two monkeys, the effect of the long-lasting dopamine depletion after reserpine (1 mg/kg IV) was followed by a repeated Scatchard procedure in up to 77 days after drug administration. The Scatchard analysis was based on two PET measurements with high and low specific radioactivity and allowed the calculation of D(1)-like dopamine receptor density (B(max)) and apparent affinity (K(D)(app)).
RESULTS: The effect of amphetamine on the B/F values was between -14 and 6%. These changes can be considered as within the range of the test-retest reliability. Thus, there was no evident effect of amphetamine-induced dopamine release on D(1)-like dopamine receptor binding. Five hours after reserpine administration, there was no change in B(max) or K(D)(app). At 3, 23, and 28 days after reserpine administration, the Scatchard analyses indicated a 13-20% reduction in B(max) without any evident change in K(D)(app) in both the striatum and the neocortex.
CONCLUSIONS: The lack of evident effects of amphetamine and reserpine on D(1)-like dopamine receptor binding is markedly different from the 20% amphetamine-induced decrease and 50% reserpine-induced increase that has been consistently reported for D(2)-like dopamine receptor binding. The data indicated that D(1)-like dopamine receptor occupancy of endogenous dopamine is low at physiological condition. It is thus unlikely that D(1)-like dopamine receptor radioligands can be used to measure changes in the concentration of endogenous dopamine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10525759     DOI: 10.1007/s002130051110

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  17 in total

1.  Prefrontal dopamine D1 receptors and working memory in schizophrenia.

Authors:  Anissa Abi-Dargham; Osama Mawlawi; Ilise Lombardo; Roberto Gil; Diana Martinez; Yiyun Huang; Dah-Ren Hwang; John Keilp; Lisa Kochan; Ronald Van Heertum; Jack M Gorman; Marc Laruelle
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

2.  Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study.

Authors:  Yuan-Hwa Chou; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2006-01-05       Impact factor: 4.530

3.  Expanding the geography of epilepsy: imaging evidence for Basal Ganglia involvement.

Authors:  William H Theodore
Journal:  Epilepsy Curr       Date:  2006 Mar-Apr       Impact factor: 7.500

Review 4.  Testing for radioligand sensitivity to endogenous neurotransmitter release.

Authors:  Gitte M Knudsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

Review 5.  News and views on in-vivo imaging of neurotransmission using PET and MRI.

Authors:  Christin Y Sander; Swen Hesse
Journal:  Q J Nucl Med Mol Imaging       Date:  2017-07-27       Impact factor: 2.346

6.  Striatal dopamine D1-like receptor binding is unchanged in primary focal dystonia.

Authors:  Morvarid Karimi; Stephen M Moerlein; Tom O Videen; Yi Su; Hubert P Flores; Joel S Perlmutter
Journal:  Mov Disord       Date:  2013-10-21       Impact factor: 10.338

Review 7.  Application and implementation of selective tissue microdissection and proteomic profiling in neurological disease.

Authors:  Jay Jagannathan; Jie Li; Nicholas Szerlip; Alexander O Vortmeyer; Russell R Lonser; Edward H Oldfield; Zhengping Zhuang
Journal:  Neurosurgery       Date:  2009-01       Impact factor: 4.654

8.  An integrative model of Parkinson's disease treatment including levodopa pharmacokinetics, dopamine kinetics, basal ganglia neurotransmission and motor action throughout disease progression.

Authors:  Florence Véronneau-Veilleux; Philippe Robaey; Mauro Ursino; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-10-21       Impact factor: 2.745

9.  A receptor-based model for dopamine-induced fMRI signal.

Authors:  Joseph B Mandeville; Christin Y M Sander; Bruce G Jenkins; Jacob M Hooker; Ciprian Catana; Wim Vanduffel; Nathaniel M Alpert; Bruce R Rosen; Marc D Normandin
Journal:  Neuroimage       Date:  2013-03-01       Impact factor: 6.556

10.  Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112.

Authors:  Dara M Cannon; Jacqueline M Klaver; Summer A Peck; Denise Rallis-Voak; Kristine Erickson; Wayne C Drevets
Journal:  Neuropsychopharmacology       Date:  2008-10-22       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.